Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01448005 · ClinicalTrials.gov registry record
LifeVest Post-CABG Registry
A clinical trial, sponsored by Zoll Medical Corporation.
- Terminated
- Registry status
- 69
- Enrollment target
NCT01448005: Clinical Trial study, sponsored by Zoll Medical Corporation.
NCT01448005 is a clinical trial that was terminated before completion, run by Zoll Medical Corporation. The registered enrollment target is 69 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01448005 was terminated before completion, sponsored by Zoll Medical Corporation.
- TERMINATED
- Registry status
- 69 participants
- Enrollment target
Study Summary
This is a multi-center prospective registry of patients with an ejection fraction (EF) ≤ 35% following coronary artery bypass graft (CABG) surgery in order to test the hypothesis that wearable defibrillators (WD) will decrease overall mortality after discharge by decreasing arrhythmic death in this select population with high risk for sudden cardiac death (SCD). This is a pilot project to determine the feasibility of a larger-scale study.
Interventions
- DEVICE wearable defibrillator (LifeVest)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2011-02 |
| Est. Completion | 2014-10 |
Why NCT01448005 stopped before completion
NCT01448005 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 69 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which wearable defibrillator (LifeVest) is the first listed.
NCT01448005 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01448005 about?
NCT01448005 is a clinical study titled "LifeVest Post-CABG Registry". This is a multi-center prospective registry of patients with an ejection fraction (EF) ≤ 35% following coronary artery bypass graft (CABG) surgery in order to test the hypothesis that wearable defibrillators (WD) will decrease overall mortality after discharge by decreasing arrhythmic death in this ...
What is the current status of trial NCT01448005?
This trial is currently terminated. The enrollment target is 69 participants. The study started on 2011-02. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01448005?
The interventions under investigation include: wearable defibrillator (LifeVest) (DEVICE).
Who is sponsoring clinical trial NCT01448005?
This trial is sponsored by Zoll Medical Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia